These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2850378)

  • 1. [Clinical evaluation of serum CA125 in patients with hepatocellular carcinoma].
    Ohgi N; Horie Y; Maeda N; Hirayama C
    Nihon Shokakibyo Gakkai Zasshi; 1988 Oct; 85(10):2239-42. PubMed ID: 2850378
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
    Fabris C; Basso DA; Leandro G; Meggiato T; Elba S; Panozzo MP; Del Favero G; Fogar P; Di Mario F; Naccarato R
    Cancer; 1991 Oct; 68(8):1795-8. PubMed ID: 1717126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of TAC-41 assay as a tumor marker].
    Ariyoshi Y; Kuwabara M; Iwakoshi N; Kito K
    Nihon Rinsho; 1990 Feb; 48 Suppl():1060-3. PubMed ID: 2162412
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumour markers of hepatocellular carcinoma.
    Kew MC
    J Gastroenterol Hepatol; 1989; 4(4):373-84. PubMed ID: 2562350
    [No Abstract]   [Full Text] [Related]  

  • 5. Do CA 19-9 and TPA play a minor role as compared to AFP in diagnosing primary hepatocellular carcinoma?
    Leandro G; Zizzari S; Fabris C; Basso D; Elba S; Del Favero G; Meggiato T; Angonese C; Di Mario F; Manghisi OG
    Oncology; 1989; 46(6):381-5. PubMed ID: 2479897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of a monoclonal antibody to serum KM01 for the diagnosis of hepatocellular carcinoma.
    Fujii T; Horie Y; Ikuta Y; Nishimuki E; Murawaki Y; Suou T; Kawasaki H
    Clin Chim Acta; 1995 Apr; 236(1):71-9. PubMed ID: 7545092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment.
    Trojan J; Raedle J; Zeuzem S
    Digestion; 1998 Jul; 59 Suppl 2():72-4. PubMed ID: 9718428
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarkers for early diagnosis of hepatocellular carcinoma.
    Forner A; Bruix J
    Lancet Oncol; 2012 Aug; 13(8):750-1. PubMed ID: 22738800
    [No Abstract]   [Full Text] [Related]  

  • 9. History and recent progress in evaluation of the fucosylated alpha-fetoprotein fraction.
    Aoyagi Y; Tamura Y; Suda T
    J Gastroenterol Hepatol; 2011 Apr; 26(4):615-6. PubMed ID: 21418297
    [No Abstract]   [Full Text] [Related]  

  • 10. Dickkopf-1 and hepatocellular carcinoma.
    Tsai JF; Jeng JE; Chuang WL
    Lancet Oncol; 2012 Oct; 13(10):e410; author reply e410-1. PubMed ID: 23026825
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of sialylated LewisX as a tumor-associated carbohydrate antigen in the sera of patients with gastric cancer].
    Nakagoe T; Hirota M; Hiratani K; Fukushima K; Shimoyama T; Miura T; Tomita M; Hara K; Ifuku M
    Gan No Rinsho; 1989 Mar; 35(4):455-61. PubMed ID: 2565987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.
    Van Hees S; Michielsen P; Vanwolleghem T
    World J Gastroenterol; 2016 Oct; 22(37):8271-8282. PubMed ID: 27729734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
    J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous drastic reduction of alpha-fetoprotein in hepatocellular carcinoma.
    Phadke AY; Desai HG
    Indian J Gastroenterol; 1996 Jul; 15(3):111. PubMed ID: 8840646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma producing carcinoembryonic antigen and carbohydrate antigen 19-9.
    Usui Y; Miura H; Kimura Y; Takayama S; Nakayama M
    Intern Med; 1992 Jun; 31(6):791-3. PubMed ID: 1327309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma.
    Shirabe K; Toshima T; Kimura K; Yamashita Y; Ikeda T; Ikegami T; Yoshizumi T; Abe K; Aishima S; Maehara Y
    Liver Int; 2014 Jul; 34(6):937-41. PubMed ID: 24393295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on "Profiling serologic biomarkers in cirrhotic patients via high-throughput Fourier transform infrared spectroscopy: toward a new diagnostic tool of hepatocellular carcinoma".
    Lewis PD
    Transl Res; 2013 Nov; 162(5):275-8. PubMed ID: 24035850
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatocellular carcinoma tumour markers: current role and expectations.
    Rich N; Singal AG
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):843-53. PubMed ID: 25260312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
    Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
    Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: clinical features, evaluation and treatment.
    Khurshid H; Malik IA
    J Pak Med Assoc; 1995 May; 45(5):136-43. PubMed ID: 7563580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.